Lorlatinib is a cyclic ether and organic heterotetracyclic compound with the structure of 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted with methyl groups at positions 2 and 10R, a cyano group at position 3, an amino group at position 7, and a fluoro group at position 12. It is a small molecule inhibitor of ALK and ROS1 kinases developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. It functions as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It belongs to the classes of pyrazoles, monofluorobenzenes, aromatic ethers, nitriles, benzamides, azamacrocycles, aminopyridines, and cyclic ethers.
